Co-morbidity, ageing and predicted mortality in antiretroviral treated Australian men: a quantitative analysis.
BACKGROUND:Life expectancy has increased in HIV-positive individuals receiving combination antiretroviral therapy (cART); however, they still experience increased mortality due to ageing-associated comorbidities compared with HIV-negative individuals. METHODS:A retrospective study of 314 Queensland...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2013-01-01
|
| Series: | PLoS ONE |
| Online Access: | http://europepmc.org/articles/PMC3808383?pdf=render |
| _version_ | 1818980415856181248 |
|---|---|
| author | Luis Furuya-Kanamori Mark D Kelly Samantha J McKenzie |
| author_facet | Luis Furuya-Kanamori Mark D Kelly Samantha J McKenzie |
| author_sort | Luis Furuya-Kanamori |
| collection | DOAJ |
| description | BACKGROUND:Life expectancy has increased in HIV-positive individuals receiving combination antiretroviral therapy (cART); however, they still experience increased mortality due to ageing-associated comorbidities compared with HIV-negative individuals. METHODS:A retrospective study of 314 Queensland HIV-infected males on cART was conducted. The negative impact of ageing was assessed by estimating the probability of 5-year mortality; comparisons were made between an HIV-specific predictive tool (VACS index) and the Australian Bureau of Statistics (ABS) life-tables to examine potential differences attributed to HIV. The negative impact of ageing was also assessed by the prevalence of comorbidities. Associations between comorbidity and estimates of predicted mortality by regression analysis were assessed. RESULTS:The mean predicted 5-year mortality rate was 6% using the VACS index compared with 2.1% using the ABS life-table (p<0.001). The proportion of patients at predicted high risk of mortality (>9%) using the VACS index or ABS life-table were 17% and 1.8% respectively. Comorbidities were also more prevalent in this cohort compared with rates of comorbidities in age-matched Australian men from the general population. Metabolic disease (38.2%) was the most prevalent comorbidity followed by renal (33.1%) and cardiovascular disease (23.9%). Multivariate analysis demonstrated that patients with a history of cardiovascular disease had a higher predicted risk of mortality (OR=1.69;95%CI:1.17-2.45) whereas ex-smokers had a lower predicted risk of mortality (OR=0.61;95%CI:0.41-0.92). CONCLUSIONS:Using the VACS Index there is an increased predicted risk of mortality in cART-treated HIV infected Australian men compared with age-matched men using the ABS data. This increased predicted mortality risk is associated with cardiovascular disease and the number of comorbidities per subject; which suggests that the VACS Index may discriminate between high and low predicted mortality risks in this population. However, until the VACS Index is validated in Australia this data may suggest the VACS Index overestimates predicted mortality risk in this country. |
| first_indexed | 2024-12-20T17:15:04Z |
| format | Article |
| id | doaj.art-e6fcbbda7cfe4b07ae58f13b5d2b47c9 |
| institution | Directory Open Access Journal |
| issn | 1932-6203 |
| language | English |
| last_indexed | 2024-12-20T17:15:04Z |
| publishDate | 2013-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj.art-e6fcbbda7cfe4b07ae58f13b5d2b47c92022-12-21T19:32:04ZengPublic Library of Science (PLoS)PLoS ONE1932-62032013-01-01810e7840310.1371/journal.pone.0078403Co-morbidity, ageing and predicted mortality in antiretroviral treated Australian men: a quantitative analysis.Luis Furuya-KanamoriMark D KellySamantha J McKenzieBACKGROUND:Life expectancy has increased in HIV-positive individuals receiving combination antiretroviral therapy (cART); however, they still experience increased mortality due to ageing-associated comorbidities compared with HIV-negative individuals. METHODS:A retrospective study of 314 Queensland HIV-infected males on cART was conducted. The negative impact of ageing was assessed by estimating the probability of 5-year mortality; comparisons were made between an HIV-specific predictive tool (VACS index) and the Australian Bureau of Statistics (ABS) life-tables to examine potential differences attributed to HIV. The negative impact of ageing was also assessed by the prevalence of comorbidities. Associations between comorbidity and estimates of predicted mortality by regression analysis were assessed. RESULTS:The mean predicted 5-year mortality rate was 6% using the VACS index compared with 2.1% using the ABS life-table (p<0.001). The proportion of patients at predicted high risk of mortality (>9%) using the VACS index or ABS life-table were 17% and 1.8% respectively. Comorbidities were also more prevalent in this cohort compared with rates of comorbidities in age-matched Australian men from the general population. Metabolic disease (38.2%) was the most prevalent comorbidity followed by renal (33.1%) and cardiovascular disease (23.9%). Multivariate analysis demonstrated that patients with a history of cardiovascular disease had a higher predicted risk of mortality (OR=1.69;95%CI:1.17-2.45) whereas ex-smokers had a lower predicted risk of mortality (OR=0.61;95%CI:0.41-0.92). CONCLUSIONS:Using the VACS Index there is an increased predicted risk of mortality in cART-treated HIV infected Australian men compared with age-matched men using the ABS data. This increased predicted mortality risk is associated with cardiovascular disease and the number of comorbidities per subject; which suggests that the VACS Index may discriminate between high and low predicted mortality risks in this population. However, until the VACS Index is validated in Australia this data may suggest the VACS Index overestimates predicted mortality risk in this country.http://europepmc.org/articles/PMC3808383?pdf=render |
| spellingShingle | Luis Furuya-Kanamori Mark D Kelly Samantha J McKenzie Co-morbidity, ageing and predicted mortality in antiretroviral treated Australian men: a quantitative analysis. PLoS ONE |
| title | Co-morbidity, ageing and predicted mortality in antiretroviral treated Australian men: a quantitative analysis. |
| title_full | Co-morbidity, ageing and predicted mortality in antiretroviral treated Australian men: a quantitative analysis. |
| title_fullStr | Co-morbidity, ageing and predicted mortality in antiretroviral treated Australian men: a quantitative analysis. |
| title_full_unstemmed | Co-morbidity, ageing and predicted mortality in antiretroviral treated Australian men: a quantitative analysis. |
| title_short | Co-morbidity, ageing and predicted mortality in antiretroviral treated Australian men: a quantitative analysis. |
| title_sort | co morbidity ageing and predicted mortality in antiretroviral treated australian men a quantitative analysis |
| url | http://europepmc.org/articles/PMC3808383?pdf=render |
| work_keys_str_mv | AT luisfuruyakanamori comorbidityageingandpredictedmortalityinantiretroviraltreatedaustralianmenaquantitativeanalysis AT markdkelly comorbidityageingandpredictedmortalityinantiretroviraltreatedaustralianmenaquantitativeanalysis AT samanthajmckenzie comorbidityageingandpredictedmortalityinantiretroviraltreatedaustralianmenaquantitativeanalysis |